Molecular Design
SEPTEMBER 18, 2024
In the Compatibility Issues section the authors state: Looking beyond laboratory-to-laboratory variability of assays that are nominally the same, there are numerous reasons why literature results for different assays measured against the same “target” may not be comparable.
Molecular Design
DECEMBER 19, 2023
Regardless of whether binding to target is covalent or non-covalent, the concentration and affinity of substrates (as well as cofactors such as ATP) need be properly accounted for when interpreting effects of chemical probes in cell-based assays. As measurement of k.inact/K.i values for a covalent chemical probe.]
Agency IQ
APRIL 12, 2024
For example, in describing how potency should be demonstrated for CGT products, the 2011 guidance simply stated that potency for gene therapy products is derived from “at least two biological activities for its potency: the ability to transfer a genetic sequence to a cell; and the biological effect of the expressed genetic sequence.”
Expert insights. Personalized for you.
69 
Let's personalize your content